Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Arrowhead Pharmaceuticals, Inc.    ARWR

ARROWHEAD PHARMACEUTICALS, INC.

(ARWR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

Arrowhead Pharmaceuticals : to Participate in Upcoming June 2020 Conferences

share with twitter share with LinkedIn share with facebook
05/28/2020 | 07:32am EDT

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) today announced that it is scheduled to participate in the following upcoming events:

Jefferies Virtual Healthcare Conference – June 2-4, 2020

June 4, 2:00 p.m. EDT – Chris Anzalone, Ph.D., Arrowhead’s president and CEO, will participate in a fireside chat presentation

Goldman Sachs 41st Annual Global Healthcare Conference – June 9-11, 2020

June 10, 11:20 a.m. EDT – Dr. Anzalone will participate in a fireside chat presentation

A copy of the presentation materials and webcast links, if the presentation is being webcast, may be accessed on the Events and Presentations page under the Investors section of the Arrowhead website.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.

For more information, please visit www.arrowheadpharma.com, or follow us on Twitter @ArrowheadPharma. To be added to the Company's email list and receive news directly, please visit http://ir.arrowheadpharma.com/email-alerts.

Safe Harbor Statement under the Private Securities Litigation Reform Act:

This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties, including the safety and efficacy of our product candidates, the duration and impact of regulatory delays in our clinical programs, our ability to finance our operations, the likelihood and timing of the receipt of future milestone and licensing fees, the future success of our scientific studies, our ability to successfully develop and commercialize drug candidates, the timing for starting and completing clinical trials, rapid technological change in our markets, and the enforcement of our intellectual property rights. Our most recent Annual Report on Form 10-K and subsequent Quarterly Reports on Form 10-Q discuss some of the important risk factors that may affect our business, results of operations and financial condition. We assume no obligation to update or revise forward-looking statements to reflect new events or circumstances.

Source: Arrowhead Pharmaceuticals, Inc.


© Business Wire 2020
share with twitter share with LinkedIn share with facebook
Latest news on ARROWHEAD PHARMACEUTICALS,
07/09ARROWHEAD PHARMACEUTICALS : to Host Key Opinion Leader Webinar on ARO-ENaC for T..
BU
07/08ARROWHEAD PHARMACEUTICALS : to Webcast Fiscal 2020 Third Quarter Results
BU
05/28ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming June 2020 Conferences
BU
05/07ARROWHEAD PHARMACEUTICALS : MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CO..
AQ
05/07ARROWHEAD PHARMACEUTICALS, INC. : Results of Operations and Financial Condition,..
AQ
05/07ARROWHEAD PHARMACEUTICALS : Reports Fiscal 2020 Second Quarter Results
BU
05/04ARROWHEAD PHARMACEUTICALS : Announces Retirement of COO Bruce Given
AQ
05/04ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming May 2020 Conferences
AQ
05/01ARROWHEAD PHARMACEUTICALS, INC. : Change in Directors or Principal Officers (for..
AQ
05/01ARROWHEAD PHARMACEUTICALS : to Participate in Upcoming May 2020 Conferences
BU
More news
Financials (USD)
Sales 2020 90,7 M - -
Net income 2020 -64,5 M - -
Net cash 2020 197 M - -
P/E ratio 2020 -70,0x
Yield 2020 -
Capitalization 4 530 M 4 530 M -
EV / Sales 2019
EV / Sales 2020 47,8x
Nbr of Employees 134
Free-Float 97,3%
Chart ARROWHEAD PHARMACEUTICALS, INC.
Duration : Period :
Arrowhead Pharmaceuticals, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ARROWHEAD PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 10
Average target price 62,10 $
Last Close Price 44,51 $
Spread / Highest target 82,0%
Spread / Average Target 39,5%
Spread / Lowest Target -34,8%
EPS Revisions
Managers
NameTitle
Christopher Richard Anzalone President, Chief Executive Officer & Director
Douglass B. Given Chairman
Kenneth Allen Myszkowski CFO & Principal Accounting Officer
James C. Hamilton Vice President & Head-Clinical Development
Javier San Martin Chief Medical Officer
Sector and Competitors
1st jan.Capitalization (M$)
ARROWHEAD PHARMACEUTICALS, INC.-29.83%4 530
GILEAD SCIENCES, INC.17.45%95 734
VERTEX PHARMACEUTICALS34.48%76 344
REGENERON PHARMACEUTICALS65.35%63 051
WUXI APPTEC CO., LTD.53.97%33 311
GENMAB A/S56.13%22 955